people with HBV infection
Hepatitis B virus (HBV) is the world’s most common serious liver infection, with an estimated 292 million people with HBV infection. Current therapies for HBV aim to suppress the virus but do not reduce HBV levels to permanently harmless levels after stopping treatment, which is known as a “functional cure.”
Chronic HBV infection, a condition characterized by the presence of the HBV surface antigen (HBsAg) for six months or more, claims more than 887,000 lives annually.
We are developing DCR-HBVS, now referred to as RG6346, in collaboration with Roche for the treatment of chronic HBV infection in adults. Unlike current therapies that typically provide long-term suppression of the virus, RG6346 has the potential to provide a functional cure for patients living with chronic HBV.
- Razavi-Shearer D, Gamkrelidze I, Nguyen MH et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018; 3(6):383-403.
- World Health Organization. Finding a cure for hepatitis B: are we close? https://www.who.int/hepatitis/news-events/hbv-cure-overview/en/. Accessed Dec. 30, 2019.
Resources for patients with HBV
The following organizations provide educational resources and support research to help people living with HBV.
The Hepatitis B Foundation is dedicated to finding a cure and improving the quality of life for those affected by hepatitis B worldwide. Its work includes funding focused research, promoting disease awareness, supporting immunization and treatment initiatives, and serving as a source of information for patients and their families, the medical and scientific community, and the general public.
The World Hepatitis Alliance (WHO) is dedicated to harnessing the power of people living with viral hepatitis to achieve its elimination. The WHO works with governments, national members and other key partners to raise awareness, influence policy change and drive action to find the millions of people unaware of their condition.